Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
ARUP Laboratories, |
RCV000526897 | SCV001477676 | likely benign | not provided | 2020-01-20 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001404571 | SCV001606474 | likely benign | Hypertrophic cardiomyopathy 14 | 2024-04-25 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002350320 | SCV002649827 | likely benign | Cardiovascular phenotype | 2018-01-25 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV004543183 | SCV004758249 | likely benign | MYH6-related disorder | 2020-09-18 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |